Debbie Rigby rounds up the latest in research news
A systematic review and meta-analysis of randomized trials indicates that low-dose colchicine reduced the risk of MACE as well as that of myocardial infarction, stroke, and the need for coronary revascularization in a broad spectrum of patients with coronary disease. There was no difference in all-cause mortality and fewer cardiovascular deaths were counterbalanced by more non-cardiovascular deaths.
European Heart Journal, ehab115
This review provides an up-to-date guide for antithrombotic therapy for the management of coronary artery disease, cerebrovascular disease and peripheral artery disease in people with diabetes. Primary prevention with antiplatelet agents, mainly aspirin, should only be considered in higher-risk individuals. In stable atherosclerotic disease, the combination of aspirin and very-low-dose rivaroxaban is useful, particularly in the presence of PAD.
European Heart Journal 2021.
Anticholinergic medications are associated with a wide range of adverse effects to which elderly patients are particularly susceptible. This article discusses the various ways that anticholinergic burden can be measured, how these can be used to help clinicians identify patients at risk from the adverse effects of anticholinergics, and how to address these risks.
Prescriber, first published 23 March 2021.
Concomitant opioids and antidepressants may increase the risk of serotonergic effects and other toxicity, or reduce analgesic efficacy. Some opioids such as tramadol, pethidine, dextromethorphan and tapentadol increase serotonergic activity. Some selective serotonin reuptake inhibitors block the metabolism of opioids. This may reduce the concentrations and analgesic effect of some opioids such as codeine and tramadol, and increase the concentrations and risk of adverse effects of other opioids such as methadone.
Aust Prescr 2021;44:41-4.